ArticlePLOS global public health2025
Acceptability and feasibility of integrating female genital schistosomiasis and sexual and reproductive health interventions in Kenya: A demonstration study.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From devolution to post-COVID-19 UHC scoping review of human resource for health reforms in Kenya: a signalling and sensemaking analysis.Frontiers in health services · 2026Article
- Now, more than ever, it's time to address the neglect of female genital schistosomiasis.Parasitology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Female genital schistosomiasis (FGS) is a neglected gynaecological condition that is a manifestation of chronic urogenital schistosomiasis. This disease has significant implications for the reproductive health and overall well-being of women and girls, especially in areas with limited access to water, sanitation, and hygiene (WASH). In Kenya, where urogenital schistosomiasis is endemic, the burden of FGS and how to best address it within existing sexual and reproductive health (SRH) services has not been fully explored. This mixed-methods study applied an implementation research approach to assess the feasibility and acceptability of integrating FGS services into routine SRH interventions across public health facilities in three high schistosomiasis endemic counties in Kenya. The intervention included implementing a minimum service package, between December 2023 and December 2024, encompassing health literacy, screening, diagnosis, and treatment. A total of 8,856 women were screened for FGS, with an overall estimated positivity rate of 27.7% (95% CI [26.7, 28.7]). A quantitative survey with a subset of 1,041 clients revealed high acceptability of integration 98.8% (95% CI [98, 99.3]). Integration enabled diagnosis and highlighted a hidden burden of FGS. Qualitative findings revealed significant gaps in knowledge and awareness, stigma-related barriers, and the absence of standardised indicators in the Kenya Health Information System (KHIS), which hampers effective data collection, reporting, and resource planning, including procurement of praziquantel. These findings show the urgent need for health system improvements, including the integration of standardised FGS indicators into the KHIS, to support surveillance, preparedness, and equitable resource distribution, the need for inclusion of FGS within medical training curricula, and for normative clinical guidance on FGS. The evidence supports scaling up FGS-SRH integration and positions MCH clinics and outreach programs as critical entry points.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.